Peptide Oligonucleotide Conjugate Market Size is predicted to grow with a 12.5% CAGR during the forecast period for 2025-2034.
A new class of biotherapeutics known as peptide oligonucleotide conjugates combines the selectivity of oligonucleotides with the cell-penetrating and targeting capabilities of peptides. This hybrid approach overcomes long-standing challenges in delivering genetic material across cellular membranes while retaining a high binding affinity to target sequences. Scientists have developed linker chemistries and conjugation techniques during the past ten years, creating new medicinal and diagnostic applications.
The global market for peptide and oligonucleotide conjugates is expanding significantly as a result of a number of important factors. This includes the growing need for treatments based on peptides and oligonucleotides, developments in peptide synthesis and oligonucleotide production technology, and the pharmaceutical industry's trend toward outsourcing. Additionally, the market is fueled by the rising incidence of cancer, the expanding need for tailored treatments, and developments in peptide synthesis technology.
Growing R&D expenditures, regulatory assistance, and strategic partnerships all contribute to the expansion of the peptide oligonucleotide conjugates market. However, uncontrolled toxicity that causes serious side effects is the main disadvantage of such small compounds. Furthermore, the need for a more effective treatment strategy has increased due to tumour cells' growing drug resistance to these agents, which is propelling the market for peptide oligonucleotide conjugates.
Competitive Landscape
Some of the Major Key Players in the Peptide Oligonucleotide Conjugate Market are
- Bachem Holding AG
- Integrated DNA Technologies Inc.
- LC Sciences LLC
- Bio-Synthesis Inc.
- GeneDesign Inc.
- Creative Peptides
- Eurogentec S.A.
- Merck KGaA
- Nitto Denko Avecia Inc.
- Thermo Fisher Scientific Inc.
- Others
Market Segmentation:
The peptide oligonucleotide conjugate market is segmented based on product type, technology, method, targeting agent, molecule type, application, chain length, linker chemistry, and end-user. Based on product type, the market is segmented into therapeutic conjugates and diagnostic conjugates. By technology, the market is segmented into liquid phase synthesis and solid phase synthesis. By method, the market is segmented into direct and indirect. By targeting agent, the market is segmented into antibodies and aptamers (RNA aptamers, DNA aptamers). By molecule type, the market is segmented into macromolecules and small molecules. By application, the market is segmented into cancer therapy (breast cancer, lung cancer, colorectal cancer {metastatic treatment, stage specific application}) and genetic disorders (cystic fibrosis, duchenne muscular dystrophy). By chain length, the market is segmented into short chain, medium chain, and long chain. By linker chemistry, the market is segmented into PEGylation and peptide linkers. By end-user, the market is segmented into biopharmaceutical companies, hospitals (private hospitals, public hospitals), and research institutes.
Based On The Product Type, The Therapeutic Conjugates Segment Is Accounted As A Major Contributor To The Peptide Oligonucleotide Conjugate Market
The therapeutic conjugates segment is expected to hold a major global market share in 2024 driven by the growing need for individualized and focused therapies. These conjugates provide better efficacy and fewer off-target effects by improving the pharmacokinetics and cellular uptake of oligonucleotide-based medications. Because therapeutic peptide-oligonucleotide conjugates can deliver therapeutic payloads selectively, their use has been further stimulated by the rise in rare diseases, genetic disorders, and chronic diseases, such as cancer. Furthermore, the pipeline of novel treatments is growing due to developments in conjugation chemistry and peptide engineering, which are drawing large investments from biopharmaceutical firms.
Cancer Therapy Segment To Witness Growth At A Rapid Rate
The growing need for tailored and focused cancer treatments is propelling the peptide oligonucleotide conjugate (POC) market's cancer therapy category's notable expansion. POCs help oligonucleotide-based medicines, which are essential for treating tumours that are hard for traditional therapies to target, by improving cellular absorption and stability. They have been a popular choice in cancer due to their capacity to deliver genetic material precisely to tumour cells while reducing off-target effects.
In The Region, The North American Peptide Oligonucleotide Conjugate Market Holds A Significant Revenue Share
The North American peptide oligonucleotide conjugate market is expected to register the highest market share in revenue in the near future fueled by substantial R&D expenditures, a cutting-edge healthcare infrastructure, and widespread use of targeted medicines. The United States is at the forefront of the region due to the increasing prevalence of cancer, growing awareness of peptide oligonucleotide conjugate therapies, and the presence of significant biotech and pharmaceutical companies.
Further factors contributing to the region's supremacy include growing clinical trial expansion, rising healthcare costs, and strengthening collaborations between biotech companies and academic institutions. In addition, the Asia Pacific is projected to grow rapidly in the global peptide oligonucleotide conjugate market, attributed to the increase in cancer cases and the strategic efforts of market participants for regional expansion in these areas. Additionally, it is projected that increased R&D and funding to create and sell these innovative delivery systems will accelerate market expansion in the area.
Peptide Oligonucleotide Conjugate Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 12.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type, Technology, Method, Targeting Agent, Molecule Type, Application, Chain Length, Linker Chemistry, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Bachem Holding AG, Integrated DNA Technologies Inc., LC Sciences LLC, Bio-Synthesis Inc., GeneDesign Inc., Creative Peptides, Eurogentec S.A., Merck KGaA, Nitto Denko Avecia Inc., Thermo Fisher Scientific Inc., and others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
